The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Depression During Pegylated Interferon-Alpha Plus Ribavirin Therapy: Prevalence and Prediction
Abstract
BACKGROUND: Interferon-alpha (IFN-alpha) plus ribavirin is used to treat hepatitis C virus (HCV) infection and is associated with a high rate of depression. Newer, pegylated preparations of IFN-alpha have a longer half-life, require once-per-week dosing, and may be associated with reduced neuropsychiatric burden. Limited data exist on depression during pegylated IFN-alpha therapy. METHOD: Depressive symptoms were assessed using the Zung Self-Rating Depression Scale (SDS) in 162 HCV-infected patients at baseline and after 4, 8, 12, and 24 weeks of treatment with pegylated IFN alpha-2b (PEG IFN) plus weight-based (N = 86) versus standard dose (N = 76) ribavirin. Data were collected from March 2001 to April 2003. RESULTS: Compared with baseline, mean SDS index scores were significantly increased by week 4 and remained elevated throughout the study. Thirty-nine percent of the sample experienced moderate to severe depressive symptoms (SDS index score > or = 60) at some point during PEG IFN/ribavirin therapy. Baseline depression scores significantly predicted severity of depressive symptoms during PEG IFN/ribavirin treatment (simple regression analysis: Y = 0.55X + 32.7, p < .0001). In addition, assignment to weight-based ribavirin treatment and history of depression were associated with increased likelihood of developing moderate to severe depressive symptoms (odds ratio [OR] = 2.7, 95% CI = 1.3 to 5.6, p < .01, and OR = 3.3, 95% CI = 1.3 to 8.1, p < .01, respectively). CONCLUSIONS: Development of moderate to severe depressive symptoms occurred frequently during PEG IFN/ribavirin treatment and was predicted by baseline depression scores and higher doses of ribavirin. History of major depressive disorder was also a significant predictive factor, but only through association with elevated baseline depression status. All of these factors can be evaluated and addressed to limit neuropsychiatric morbidity during HCV treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
A self-rating depression scale
ZUNG, W. W. K. (1965) · Archives of General Psychiatry · doi:10.1001/archpsyc.1965.01720310065008 · Cited by 9,813
Hapeman, D. E. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,373
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., & Margolis, H. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908193410802 · Cited by 2,992
Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa
Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Perrillo, R. P., Carey, W., Jacobson, I. M., Payne, J., Dienstag, J. L., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212203 · Cited by 1,633
Self-citation[Gastric adenocarcinoma and kidney transplantation].
Barrio, J., García-Bengoechea, M., Emparanza, J. I., & Arenas, J. I. (1998) · PubMed · Cited by 1,132
Cited by
Immune system to brain signaling: Neuropsychopharmacological implications
Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195
Self-citationInflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
“…interferon-a (IFN-a) has also been found to induce depressive symptoms, with as many as 30–50% of IFN-atreated patients meeting the symptom criteria for major depression (according to the Diagnostic and Statistical Manual IV) depending on the dose (Musselman et al, 2001; Raison et al, 2005a, b).”
BackgroundInfluentialSelf-citationDepression rating scales in Parkinson's disease: Critique and recommendations
Schrag, A., Barone, P., Brown, R. G., Leentjens, A. F. G., McDonald, W. M., Starkstein, S., Weintraub, D., Poewe, W., Rascol, O., Sampaio, C., et al. (2007) · Movement Disorders · doi:10.1002/mds.21333 · Cited by 683
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630
Self-citationMillan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Inflammation in psychiatric disorders: what comes first?
Bauer, M. E., & Teixeira, A. L. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13712 · Cited by 500
Inflammation Effects on Motivation and Motor Activity: Role of Dopamine
Felger, J. C., & Treadway, M. T. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.143 · Cited by 442
Imaging the Role of Inflammation in Mood and Anxiety-related Disorders
Felger, J. C. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666171123201142 · Cited by 427
Dahl, J., Ormstad, H., Aass, H. C. D., Malt, U. F., Bendz, L. T., Sandvik, L., Brundin, L., & Andreassen, O. A. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.03.019 · Cited by 424
Felger, J. C., & Miller, A. H. (2012) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2012.09.003 · Cited by 391
Self-citationDepression in cancer: The many biobehavioral pathways driving tumor progression
Bortolato, B., Hyphantis, T. N., Valpione, S., Perini, G., Maes, M., Morris, G., Kubera, M., Köhler, C. A., Fernandes, B. S., Stubbs, B., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.004 · Cited by 375
Screening and Management of Depression in Patients With Cardiovascular Disease
Jha, M. K., Qamar, A., Vaduganathan, M., Charney, D. S., & Murrough, J. W. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.041 · Cited by 365
Interferon pathway in SLE: one key to unlocking the mystery of the disease
Rönnblom, L., & Leonard, D. (2019) · Lupus Science & Medicine · doi:10.1136/lupus-2018-000270 · Cited by 362
Salim, S., Chugh, G., & Asghar, M. (2012) · Advances in Protein Chemistry and Structural Biology · doi:10.1016/b978-0-12-398314-5.00001-5 · Cited by 310
Extrahepatic manifestations of chronic hepatitis C virus infection
Cacoub, P., Gragnani, L., Comarmond, C., & Zignego, A. L. (2014) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.10.005 · Cited by 293
Extrahepatic manifestations of chronic hepatitis C virus infection
Cacoub, P., Comarmond, C., Domont, F., Savey, L., Desbois, A. C., & Saadoun, D. (2016) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936115585942 · Cited by 291
The molecular bases of the suicidal brain
Turecki, G. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3839 · Cited by 281
Miller, A. H. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.08.006 · Cited by 261
Self-citationThe evolutionary significance of depression in Pathogen Host Defense (PATHOS-D)
Raison, C. L., & Miller, A. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.2 · Cited by 253
Self-citationHepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., Foster, G. R., Kautz, A., Forton, D., & Pariante, C. M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.037 · Cited by 225
Self-citationBasal Ganglia Hypermetabolism and Symptoms of Fatigue during Interferon-α Therapy
Capuron, L., Pagnoni, G., Demetrashvili, M. F., Lawson, D. H., Fornwalt, F. B., Woolwine, B., Berns, G. S., Nemeroff, C. B., & Miller, A. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301362 · Cited by 229
Self-citationBull, S. J., Huezo-Diaz, P., Binder, E. B., Cubells, J. F., Ranjith, G., Maddock, C., Miyazaki, C., Alexander, N., Hotopf, M., Cleare, A. J., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.48 · Cited by 228
Self-citationFelger, J. C., Alagbe, O., Hu, F., Mook, D., Freeman, A. A., Sanchez, M. M., Kalin, N. H., Ratti, E., Nemeroff, C. B., & Miller, A. H. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.026 · Cited by 214
“Repeated Measures ANOVAs indicated that compared to saline, monkeys treated with IFNalpha exhibited increased anxiety-like behaviors (F[1,7]=7.”
BackgroundMethodInfluentialSelf-citationBermejo, P., Martín-Aragón, S., Benedí, J., Susín, C., Felici, E., Gil, P., Ribera, J. M., & Villar, Á. M. (2008) · Immunology Letters · doi:10.1016/j.imlet.2008.02.002 · Cited by 178
Serafini, G., Parisi, V. M., Aguglia, A., Amerio, A., Sampogna, G., Fiorillo, A., Pompili, M., & Amore, M. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17072393 · Cited by 172
Raison, C. L., Lowry, C. A., & Rook, G. A. W. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.161 · Cited by 169
Self-citationGlucocorticoid Dysregulations and Their Clinical Correlates: From Receptors to Therapeutics
Marques, A. H., Silverman, M. N., & Sternberg, E. M. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04987.x · Cited by 158
Inflammation and neuronal plasticity: a link between childhood trauma and depression pathogenesis
Cattaneo, A., Macchi, F., Plazzotta, G., Veronica, B., Bocchio-Chiavetto, L., Riva, M. A., & Pariante, C. M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00040 · Cited by 152
“In line with this, around the 30–40% of hepatitis C patients treated with the proinflammatory cytokine peg-interferon-alpha (pegIFN-α) develop clinically relevant depression (Miyaoka et al., 1999; Raison et al., 2005; Asnis and De La Garza, 2006).”
BackgroundRAISON, C. L., WOOLWINE, B. J., DEMETRASHVILI, M. F., BORISOV, A. S., WEINREIB, R., STAAB, J. P., ZAJECKA, J. M., BRUNO, C. J., HENDERSON, M. A., REINUS, J. F., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03316.x · Cited by 142
Self-citationDepression as a Risk Factor for Cancer: From Pathophysiological Advances to Treatment Implications
Currier, M. B., & Nemeroff, C. B. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-061212-171507 · Cited by 126
Self-citationInteroception and Inflammation in Psychiatric Disorders
Savitz, J., & Harrison, N. A. (2018) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2017.12.011 · Cited by 126
Depression and chronic liver diseases: are there shared underlying mechanisms?
Huang, X., Liu, X., & Yu, Y. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00134 · Cited by 121
Raison, C. L., Rye, D. B., Woolwine, B. J., Vogt, G. J., Bautista, B. M., Spivey, J. R., & Miller, A. H. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.019 · Cited by 116
Self-citationThe role of dopamine in inflammation-associated depression: mechanisms and therapeutic implications
Felger, J. C. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_13 · Cited by 115
Biomarkers of post-covid depression
Lorkiewicz, P., & Waszkiewicz, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184142 · Cited by 102
Altered Serum Levels of TNF-α, IL-6, and IL-18 in Depressive Disorder Patients
Fan, N., Luo, Y., Ou, Y., & He, H. (2017) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2588 · Cited by 85
Smith, A. K., Simon, J. S., Gustafson, E. L., Noviello, S., Cubells, J. F., Epstein, M. P., Devlin, D. J., Qiu, P., Albrecht, J. K., Brass, C. A., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.67 · Cited by 84
Self-citationChronic hepatitis C virus infection and depression
Adinolfi, L. E., Nevola, R., Rinaldi, L., Romano, C., & Giordano, M. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.03.007 · Cited by 59
Franzen, P. L., Buysse, D. J., Rabinovitz, M., Pollock, B. G., & Lotrich, F. E. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2009.02.011 · Cited by 62
Reber, S. O., Langgartner, D., Foertsch, S., Postolache, T. T., Brenner, L. A., Guendel, H., & Lowry, C. A. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.08.031 · Cited by 59
Glucocorticoids and Inflammation: A Double-Headed Sword in Depression?
Horowitz, M. A., Zunszain, P. A., Anacker, C., Musaelyan, K., & Pariante, C. M. (2013) · Modern Trends in Psychiatry · doi:10.1159/000343980 · Cited by 57
McNutt, M. D., Liu, S., Manatunga, A., Royster, E. B., Raison, C. L., Woolwine, B. J., Demetrashvili, M. F., Miller, A. H., & Musselman, D. L. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.330 · Cited by 56
Self-citationMinding the body: Psychotherapy and cancer survival
Spiegel, D. (2014) · British Journal of Health Psychology · doi:10.1111/bjhp.12061 · Cited by 53
Hoyo-Becerra, C., Huebener, A., Trippler, M., Lutterbeck, M., Liu, Z. J., Truebner, K., Bajanowski, T., Gerken, G., Hermann, D. M., & Schlaak, J. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083149 · Cited by 49
The Cytokine IL-17A as a Marker of Treatment Resistance in Major Depressive Disorder?
Nothdurfter, C., Milenkovic, V. M., Sarubin, N., Hilbert, S., Manook, A., Weigl, J., Almeqbaali, K., Wetzel, C. H., Rupprecht, R., & Baghai, T. C. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14636 · Cited by 38
Sharpley, A. L., Cooper, C. M., Williams, C., Godlewska, B. R., & Cowen, P. J. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4381-z · Cited by 39
Neri, S., Bertino, G., Petralia, A., Giancarlo, C., Rizzotto, A., Calvagno, G. S., Mauceri, B., Abate, G., Boemi, P., Di Pino, A., et al. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181d88af5 · Cited by 37
Raison, C. L. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_26 · Cited by 36
Self-citationChronic hepatitis C and antiviral treatment regimens: Where can psychology contribute?
Evon, D. M., Golin, C. E., Fried, M. W., & Keefe, F. J. (2013) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0029030 · Cited by 32
Schlaak, J. F., Trippler, M., Hoyo-Becerra, C., Erim, Y., Kis, B., Wang, B., Scherbaum, N., & Gerken, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038668 · Cited by 25
“The IFN-a mediated depression has been widely reported in patients treated for hepatitis B, hepatitis C and malignant melanoma and can induce to suicidal behavior [7,8,10,11].”
Background37 Drugs that act on the immune system: cytokines and monoclonal antibodies
Vial, T., Descotes, J., Braun, F., & Behrend, M. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29037-8 · Cited by 3
Metadata
- Authors
- Raison, C. L., Borisov, A. S., Broadwell, S. D., Capuron, L., Woolwine, B. J., Jacobson, I. M., Nemeroff, C. B., & Miller, A. H.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-01-15
- Volume
- 66
- Issue
- 01
- Pages
- 41-48
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2018896573
- Cited by
- 299
- References
- 50
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.